Professur für Translationale Frauenheilkunde und Geburtshilfe

Development and validation of the gene-expression Predictor of high-grade-serous Ovarian carcinoma molecular subTYPE (PrOTYPE) (2020) Talhouk A, George J, Wang C, Budden T, Tan TZ, Chiu DS, Kommoss S, et al. Journal article Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk (2020) Liu J, Prager-van der Smissen WJ, Collée JM, Bolla MK, Wang Q, Michailidou K, Dennis J, et al. Journal article Anastrozole has an Association between Degree of Estrogen Suppression and Outcomes in Early Breast Cancer and is a Ligand for Estrogen Receptor α (2020) Ingle JN, Cairns J, Suman VJ, Shepherd LE, Fasching P, Hoskin TL, Singh RJ, et al. Journal article ABC5 International Consensus Conference on Advanced Breast Cancer, Lisbon, 16 November 2019 (2020) Untch M, Würstlein R, Lüftner D, Haidinger R, Fasching P, Augustin D, Briest S, et al. Journal article, Review article Locoregional recurrence risk after neoadjuvant chemotherapy: A pooled analysis of nine prospective neoadjuvant breast cancer trials (2020) Werutsky G, Untch M, Hanusch C, Fasching P, Blohmer JU, Seiler S, Denkert C, et al. Journal article Patient-reported outcomes (PROs) in advanced breast cancer (ABC) treated with ribociclib (RIB) plus fulvestrant (FUL) as first-line (1L) and second-line (2L) therapy in MONALEESA-3 (ML-3) (2020) Fasching P, Neven P, Jerusalem G, Beck JT, Chan A, De Laurentiis M, Bianchi GV, et al. Conference contribution Predicting prognosis of breast cancer patients with brain metastases in the BMBC registry: Comparison of three different (2020) Riecke K, Mueller V, Neunhoeffer T, Weide R, Schmidt M, Park-Simon TW, Mundhenke C, et al. Conference contribution Quality-adjusted survival with ribociclib plus fulvestrant (R plus F) versus placebo plus fulvestrant (P plus F) in postmenopausal women (PMW) HR+/HER2-advanced breast cancer (ABC) based on the MONALEESA-3 trial (2020) Jerusalem G, Delea T, Martin Jimenez M, De Laurentiis M, Nusch A, Beck JT, Chan A, et al. Conference contribution Europe-side external quality assessment (EQA) of RNA based testing of ER, PR, HER2 and Ki67 in invasive breast cancer (2020) Erber R, Hartmann A, Fasching P, Stöhr R, Beckmann M, Zentgraf M, Rübner M, et al. Conference contribution A small hypoxia signature predicted pCR response to bevacizumab in the neoadjuvant GeparQuinto breast cancer trial (2020) Karn T, Meissner T, Weber KE, Solbach C, Denkert C, Engels K, Fasching P, et al. Journal article